Applied Genetic Technologies Corp. (AGTC) plans to launch a pivotal trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) by the end of this year, following strong positive six-month data from its ongoing Phase I/II trial . . .

Get GEN Edge Today!

The post AGTC Plans Pivotal Trial for XLRP Gene Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.